Detalhe da pesquisa
1.
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Lancet Oncol
; 24(10): 1073-1082, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666264